<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4DF3B36B-DFC1-41F4-BA43-548C1039E933"><gtr:id>4DF3B36B-DFC1-41F4-BA43-548C1039E933</gtr:id><gtr:name>Papworth Hospital NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Papworth Everard</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB23 3RE</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/04D63852-0F64-4229-8B07-FDBF2B06F4F1"><gtr:id>04D63852-0F64-4229-8B07-FDBF2B06F4F1</gtr:id><gtr:name>Profile Pharma Ltd.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/50CA178D-24AA-4CFC-BB08-E7A51D1D2025"><gtr:id>50CA178D-24AA-4CFC-BB08-E7A51D1D2025</gtr:id><gtr:name>Aradigm Corp</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/19D01239-9063-4914-9D02-3D494BE14627"><gtr:id>19D01239-9063-4914-9D02-3D494BE14627</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/45DBB074-4340-4301-9E07-DFED50C811D8"><gtr:id>45DBB074-4340-4301-9E07-DFED50C811D8</gtr:id><gtr:name>Chiesi</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F3436DCD-E4A9-49D6-8EA0-21D201CFFEE6"><gtr:id>F3436DCD-E4A9-49D6-8EA0-21D201CFFEE6</gtr:id><gtr:name>Actavis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4DF3B36B-DFC1-41F4-BA43-548C1039E933"><gtr:id>4DF3B36B-DFC1-41F4-BA43-548C1039E933</gtr:id><gtr:name>Papworth Hospital NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Papworth Everard</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB23 3RE</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/04D63852-0F64-4229-8B07-FDBF2B06F4F1"><gtr:id>04D63852-0F64-4229-8B07-FDBF2B06F4F1</gtr:id><gtr:name>Profile Pharma Ltd.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/50CA178D-24AA-4CFC-BB08-E7A51D1D2025"><gtr:id>50CA178D-24AA-4CFC-BB08-E7A51D1D2025</gtr:id><gtr:name>Aradigm Corp</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/19D01239-9063-4914-9D02-3D494BE14627"><gtr:id>19D01239-9063-4914-9D02-3D494BE14627</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/45DBB074-4340-4301-9E07-DFED50C811D8"><gtr:id>45DBB074-4340-4301-9E07-DFED50C811D8</gtr:id><gtr:name>Chiesi</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F3436DCD-E4A9-49D6-8EA0-21D201CFFEE6"><gtr:id>F3436DCD-E4A9-49D6-8EA0-21D201CFFEE6</gtr:id><gtr:name>Actavis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A2EE26A2-8275-447D-9B11-61E0674537F5"><gtr:id>A2EE26A2-8275-447D-9B11-61E0674537F5</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Osmond</gtr:otherNames><gtr:surname>Cookson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DD48E774-835D-4C22-A5BD-0D04C72FBD93"><gtr:id>DD48E774-835D-4C22-A5BD-0D04C72FBD93</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Loebinger</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/09AC3944-ABCE-4312-B98A-A73BFB91D312"><gtr:id>09AC3944-ABCE-4312-B98A-A73BFB91D312</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Denning</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A51DC1E1-B67E-4238-89D8-DFA52C626FBF"><gtr:id>A51DC1E1-B67E-4238-89D8-DFA52C626FBF</gtr:id><gtr:firstName>J.P</gtr:firstName><gtr:surname>Pearson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A44C438D-940B-4668-AC43-04C6A3325992"><gtr:id>A44C438D-940B-4668-AC43-04C6A3325992</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9BCFC004-2C6F-4C99-BF0A-10E399555A9C"><gtr:id>9BCFC004-2C6F-4C99-BF0A-10E399555A9C</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Muirhead</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4BD95DD2-D6B9-467C-8263-E96C17138018"><gtr:id>4BD95DD2-D6B9-467C-8263-E96C17138018</gtr:id><gtr:firstName>Alistair</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>McGuire</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5AE4ADB3-2D15-4BD9-AB04-F760B7744654"><gtr:id>5AE4ADB3-2D15-4BD9-AB04-F760B7744654</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>De Soyza</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/08E27F59-8D1B-4155-B453-30D9C83F5FDB"><gtr:id>08E27F59-8D1B-4155-B453-30D9C83F5FDB</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>Wilkinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FC303F59-8842-4BCB-A5A3-0C057B836730"><gtr:id>FC303F59-8842-4BCB-A5A3-0C057B836730</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Hubbard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2F10AC20-AF97-43B6-A1AF-7B49B8E8B00D"><gtr:id>2F10AC20-AF97-43B6-A1AF-7B49B8E8B00D</gtr:id><gtr:firstName>Anita</gtr:firstName><gtr:surname>Sullivan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/31EA9CDD-EB3E-4DDC-A413-DD43E4C40860"><gtr:id>31EA9CDD-EB3E-4DDC-A413-DD43E4C40860</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Kelleher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5271F0A4-CE52-46F2-9A0D-54B70ED51569"><gtr:id>5271F0A4-CE52-46F2-9A0D-54B70ED51569</gtr:id><gtr:firstName>Craig</gtr:firstName><gtr:surname>Winstanley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F40B6A38-1A7B-4153-A997-485BDCDF9E32"><gtr:id>F40B6A38-1A7B-4153-A997-485BDCDF9E32</gtr:id><gtr:firstName>Rodrigo</gtr:firstName><gtr:otherNames>Andres</gtr:otherNames><gtr:surname>Floto</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F36E76FC-6166-4484-B1B9-9E5E74E3A226"><gtr:id>F36E76FC-6166-4484-B1B9-9E5E74E3A226</gtr:id><gtr:firstName>Jamie</gtr:firstName><gtr:surname>Duckers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C513F7B0-CE7C-473F-AC25-6FCFAB2E9F6D"><gtr:id>C513F7B0-CE7C-473F-AC25-6FCFAB2E9F6D</gtr:id><gtr:firstName>Joseph</gtr:firstName><gtr:otherNames>Stuart</gtr:otherNames><gtr:surname>Elborn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ACE18B20-4218-4BD9-A733-D20E6FFAA05A"><gtr:id>ACE18B20-4218-4BD9-A733-D20E6FFAA05A</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:otherNames>Stuart</gtr:otherNames><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL011263%2F1"><gtr:id>DD8AFA88-BC56-46F8-96FB-E1A818B8B390</gtr:id><gtr:title>MICA: BRONCH-UK a multicentre and multidisciplinary partnership grant tackling unmet needs in bronchiectasis</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L011263/1</gtr:grantReference><gtr:abstractText>2.1 Unmet Clinical Need

Bronchiectasis (BE) is a progressive respiratory (lung) disease characterised by cough, mucus and severe, recurrent bacterial chest infections with high rates of ill health, time off work and marked reductions in health-related quality-of-life. In almost half of cases, the cause of bronchiectasis is unknown (idiopathic) and treatment in these patients remains &amp;quot;best guess&amp;quot; or symptom driven. Bronchiectasis presents a huge challenge to patients and doctors because no effective treatment is available. Both the world's first national guidelines (authored by coapplicants of this proposal) and Cochrane &amp;quot;best evidence&amp;quot; review of Bronchiectasis confirms this situation, reporting that small single-centre studies with ill-defined patient groups have hampered the few attempts to study clinical interventions /drug trials, rendering them of unproven use.

Previously the MRC sponsored UK trials in Bronchiectasis in the 1950s: Since then major developments have been sorely lacking. This partly reflects a feeling that BE is rare. However recent evidence is against this: In the UK and the US healthcare demands due to BE and mortality rates are increasing with 70,000+ hospital admissions in the UK 2011. Based on projections from US health insurance claims there are 100,000 US patients. We have limited UK data on how common this bronchiectasis is: Experts have however estimated 30-60,000 patients are affected in the UK but recent research suggests over 100,000 are affected.

Whilst the small case series reported so far demonstrate that &amp;quot;unknown cause&amp;quot; (idiopathic) and post-infectious bronchiectasis are the leading causes, bronchiectasis can also complicate common lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) or immune problems e.g. Rheumatoid arthritis. Cystic Fibrosis is an inherited (genetic) form of bronchiectasis which like COPD associated bronchiectasis has different outcomes, microbiology and management needs from Bronchiectasis. Cystic fibrosis is rare (10,000 cases in the UK) yet has made significant gains through multicentre working and coordinating research.

To date no large studies of the genetic causes of idiopathic bronchiectasis have been conducted as this requires large numbers of patients beyond that a single centre can provide. There is currently no registry of well characterised patients with Bronchiectasis anywhere outside the US. The US national registry was commenced recently and has 1200 patients that differ to UK patients. There is an urgent need to build a large cohort of UK patients with Bronchiectasis in which large enough studies can be undertaken; adding in a biobank is a key additional strength. 

Brief description of the Cohort and Partnership 
The cohort will comprise 3500 symptomatic adult patients with a High Resolution CT scans demonstrating bronchiectasis. Patients will be characterised on the basis of clinical history, clinical examination and detailed investigations that are already part of routine clinical care with yearly reviews. A DNA biobank (from a blood sample) will be collected and will form a world's first in bronchiectasis providing a unique resource allowing future genetic studies to identify underlying genetic causes &amp;amp; new targets for treatment. 

The partnership links 9 recruiting centres with established clinics &amp;amp; track records in Bronchiectasis research spread across the UK that have never had funding to work together. Additionally ground-breaking scientific partners with expertise in relevant areas will for the first time allow comprehensive mapping of the knowledge gaps. Future research will be able to use the strength of the assembled cohort; we can deliver a programme of clinical trials that address fundamental issues. 

We will therefore tackle three major unmet needs 1) Lack of expertise in the area, 2) Lack of a clinical evidence base 3) Basic science- attracting skilled scientists to work in the area.</gtr:abstractText><gtr:technicalSummary>3.1 Technical summary ; Our methodology is to

1) Set up a world leading multi-disciplinary partnership, that addresses translational gaps through collective, but never before, assembled expertise.
2) Develop industry &amp;amp; academia pre-competitive space workshops to define consensus statements, new mechanistic studies/ grants and clinical trials.
3) Biobank DNA &amp;amp; serum from 3500 well characterised databased patients with CT proven BE.
4) Create a large database of well-characterised BE patients to facilitate translational research and clinical trials. Databasing will include multiple fields aligned to national standards of care and additional fields (developed from the US Bronchiectasis database allowing international comparisons). Tagging of records to Office of National Statistics and HES data will allow prognostic indices to be developed.
5) Three Partnership pilot projects will focus on important events that have important mechanistic or pathfinding potential and mandate multicentre &amp;amp; multi-disciplinary approaches:
i) A clinimetrics study of outcome measures in BE Identify and define/ validate clinical outcome measures &amp;amp; biomarkers in an intensive pilot study of 100 patients including lung function (spirometry, lung clearance index), quality of life (QOL-B), culture and quantitative counts with exploratory biomarkers in blood &amp;amp; sputum (as compared to sputum 16SRNA microbiome). 
ii) A pilot randomised placebo controlled trial of Pseudomonas aeruginosa bacterial eradication in patients who develop their first infection. This is cross-cutting and studies both patient and bacterial factors involved in P. aeruginosa persistence (16S microbiome analysis &amp;amp; virulence marker expression and human exome sequencing) to help identify vaccine targets.
iii) Identify the prevalence of P. aeruginosa epidemic strains and compare their phenoytpe and genotypes to non-epidemic / BE adapted strains, linking to an international genome project for additional comparative power.</gtr:technicalSummary><gtr:potentialImpactText>6.1 The potential for developing new treatments and management strategies using a Bronchiectasis patient cohort was recognised by as a key priority in a roadmap exercise. Assembling this cohort of biobanked patients was chosen as the highest priority for this partnership above all other possible collaborative studies reflecting its pluripotency (see also 4.1, 5.1 &amp;amp; Pathways to Impact file).

The Bronchiectasis Patient Cohort and Biobank will have immediate and long term benefits: It will

i) provide an opportunity for basic science researchers to study a ready assembled well characterised cohort / select particular phenotypes of interest.
ii) identify new targets for drug therapy in the first translational gap through basic science studies.
iii) enable meaningful intervention studies in both the academic and pharmaceutical industry field. 
iv) provide information to patients and their families which will help them manage or prevent complications of Bronchiectasis. 
v) it will directly shape future patient care through mapping of outcomes and mortality.
vi) inform Department of Health &amp;amp; NHS commissioners of treatment burdens and healthcare use.
vii) allow development of better clinical guidelines for clinicians. 

Impact on the first translational gap

Two key drawbacks to tackling &amp;quot;first translational&amp;quot; evidence gaps in bronchiectasis are; 
1) The lack of a basic science roadmap of discovery in the field.
2) A lack of a large well characterised cohort that is adequately powered.
These have collectively resulted in understandable barriers to grant awards and successful research in the field. To date, for example, the MRC has funded only 1 study in bronchiectasis in the last 15 years. The impact of the partnership will be to identify such a roadmap across a broad range of scientific disciplines and secondly provide the cohort that is phenotyped/ characterised enough and in sufficient numbers to remove such concerns.

Impact on patient care - development of clinical guidelines. 

An accessible, clearly defined patient cohort would fulfil an unmet clinical need to evaluate and optimise current management strategies and provide evidence-based clinical guidelines. It would also be possible to assess disease progression and the impact of physiotherapy on this progression.

Impact on clinical research and trials. 

The reasons for variation in progression and the factors that ultimately determine this in bronchiectasis remain unclear. This cohort will be utilised to explore genotype-phenotype correlations in more detail by analysing the physiological, environmental and genetic factors that may be relevant to disease expression. The proposed cohort would also provide sufficient power to assess the efficacy of potential disease-modifying drugs, or novel interventional therapies such as inhaled antibiotic therapy. Proposed joint workshops with academic clinicians, regulatory authorities are expected to improve trials design, feasibility and regulatory approvals. The number and type of studies will be limited by recruitment of the various subgroups of interest e.g. Pseudomonas infected or na&amp;iuml;ve. Based on projections we would expect to secure funding for and conduct least 3 major interventional studies and 6 observational/proof of principle studies during the 5-year period of funding. Studies are likely to be in the region of 3 months to 3 years duration.

Impact of 'added value'. 

This cohort will underpin multiple new studies that would have previously been impossible. This will support the work of multiple scientific beneficiaries across genetics, microbiology, proteomics and immunology. 
The recent establishment of a US national database presents a unique opportunity for the field to have truly comparable outcomes. The ability to make a real impact on the lives of patients with this progressive and disabling disease will develop best through a global perspective as afforded by such comparative data.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>711388</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Profile Pharma Ltd.</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BronchUK members as leads on PROMIS trial</gtr:description><gtr:id>59F30550-86F7-4214-A471-9BA05EF43D95</gtr:id><gtr:impact>Findings from the trial were published in American Journal of Respiratory and Critical Care Medicine in 2014, doi: 10.1164/rccm.201312-2208OC</gtr:impact><gtr:partnerContribution>Profile Pharma Ltd (UK) acted as both funder and sponsor.</gtr:partnerContribution><gtr:piContribution>BronchUK member C Haworth and BronchUK affiliate D Bilton were leads on this pharma sponsored trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aradigm Corp</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>BronchUK members advised on ORBIT-3 trial</gtr:description><gtr:id>48DAC924-6C3D-4118-85B1-DB73843C6223</gtr:id><gtr:impact>No outputs so far.</gtr:impact><gtr:partnerContribution>Aradigm Corp acted as both sponsor and funder on the trial.</gtr:partnerContribution><gtr:piContribution>BronchUK member C Haworth and BronchUK affiliate D Bilton advised on this pharma led study.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gilead</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Industry partner funding - Gilead</gtr:description><gtr:id>F4397EF6-7B8F-49CF-A640-6217A0E7A35B</gtr:id><gtr:impact>No outputs so far.</gtr:impact><gtr:partnerContribution>Gilead provided funding to increase the consortium's impact and influence and to extend the cohort study.</gtr:partnerContribution><gtr:piContribution>BronchUK have used this funding to increase the consortium's impact and influence and to extend the cohort study.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>6C65A6D8-DD7A-4125-BE8B-FF3FA915B9CB</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>BronchUK members lead on RESPIRE-1 trial</gtr:description><gtr:id>7215712C-8657-4690-A414-3B1D50B2EB22</gtr:id><gtr:impact>Presented in Keynote session as oral presentation at ERS meeting 2016. Manuscript in prep.</gtr:impact><gtr:partnerContribution>Bayer HealthCare acted as sponsor and funder on this trial.</gtr:partnerContribution><gtr:piContribution>BronchUK member A De Soyza and BronchUK affiliate R Wilson were key leads on the pharma led RESPIRE-1 trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>CF1ED38C-E984-4AF3-A2DB-8718F6991F11</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aradigm Corp</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>BronchUK members advise on ORBIT Phase 2 trial</gtr:description><gtr:id>3F8E431F-F47E-4830-8CBB-5C8A52E00F67</gtr:id><gtr:impact>The findings on this trial were published in Thorax in 2013, doi:10.1136/thoraxjnl-2013-203207.</gtr:impact><gtr:partnerContribution>Aradigm Corp funded and sponsored this trial.</gtr:partnerContribution><gtr:piContribution>BronchUK members D Bilton and A De Soyza advised on this pharma funded trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chiesi</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Industry partner funding - Chiesi</gtr:description><gtr:id>3C0EF561-A5EF-4E92-91A4-E50C8165B084</gtr:id><gtr:impact>No outputs so far.</gtr:impact><gtr:partnerContribution>Chiesi provided funding to increase the consortium's impact and influence and to extend the cohort study.</gtr:partnerContribution><gtr:piContribution>BronchUK have used this funding to increase the consortium's impact and influence and to extend the cohort study.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>CAAC5A1E-4D54-45D6-B715-0137C0D303EC</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>DD90CCA2-EC4C-4F08-8BF0-D377C557B1DD</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine Edinburgh</gtr:department><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>5DCC5544-B0B5-4C2D-92D7-2CD6ADE29667</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University of Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>91E59B51-F6A0-4813-8A36-5D585BF2E379</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>418BDCDD-A3A5-4583-BB6B-EEE32C5B3721</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Papworth Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>F967D223-B7C5-4B16-98FD-2B8474E57457</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Industry partner funding - GSK</gtr:description><gtr:id>FDD66139-4C10-44A3-B2D4-40E5D3AE098C</gtr:id><gtr:impact>No outputs so far.</gtr:impact><gtr:partnerContribution>GSK provided funding to increase the consortium's impact and influence and to extend the cohort study.</gtr:partnerContribution><gtr:piContribution>BronchUK have used thisfunding to increase the consortium's impact and influence and to extend the cohort study.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London (ICL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>576A77D8-5B22-40D8-A3C3-DAFE485343D1</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Members of the Bronch-UK consortium</gtr:description><gtr:id>ED557AD1-4CD6-4D6F-AF03-E424B4F29AD7</gtr:id><gtr:impact>Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; 
clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A &amp;pound;1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.</gtr:impact><gtr:partnerContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:partnerContribution><gtr:piContribution>Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Actavis</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Industry Partner Funding - Novartis</gtr:description><gtr:id>BB058B88-AEC4-4C7A-81FA-048F3D0D96EC</gtr:id><gtr:impact>No outputs so far.</gtr:impact><gtr:partnerContribution>Actavis provided funding to increase the consortium's impact and influence and to extend the cohort study.</gtr:partnerContribution><gtr:piContribution>BronchUK have used the funding to increase the consortium's impact and influence and to extend the cohort study.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British Thoracic Society Meeting Presentation December 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>987505B2-5D81-4009-B39B-850073A4D86B</gtr:id><gtr:impact>Tony De Soyza presented a talk on Bronchiectasis Pipelines and Networks to give the audience an update on developments in
Bronchiectasis and outline pipelines of new studies &amp;amp; therapies in the field.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.bronch.ac.uk/Contents/Item/Display/92</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BronchUK Twitter Account</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1203E559-4D4A-4D22-BC2D-D84CBEACF753</gtr:id><gtr:impact>A BronchUK twitter account has been created to increase the consortium's visibility among the public and to network with supporters, practitioners in the field, industry and patients.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://twitter.com/Bronch_UK</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at British Thoracic Society Meeting, December 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>87439ED0-EF01-4ADE-BE79-ED90E0DFC78C</gtr:id><gtr:impact>Presentation at the British Thoracic Society Meeting</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Meeting on Asthma COPD and Concomitant Chronic Diseases Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1360B557-C177-4388-BB5E-62288D6C6E5F</gtr:id><gtr:impact>Tony De Soyza gave a talk at the meeting at the International Meeting on Asthma, COPD and Concomitant Chronic Diseases held in Firenze, Italy 5-7 March 2015.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.bronch.ac.uk/Contents/Item/Display/97</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Thoracic Society Meeting Presentation December 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E29ED46A-DDF5-460E-AC82-643ACC8C846F</gtr:id><gtr:impact>Two presentations at the British Thoracic Society Meeting December 2015:

Anthony De Soyza - Talk on Sputum Neutrophils but not Interleukin-8 (IL-8) or Interleukin-17 (IL-17) correlate with the Bronchiectasis Severity Index (BSI).
Vidya Navaratnam - Poster on admission trends and outcomes of individuals with bronchiectasis admitted to adult general critical care units in England, Wales and Northern Ireland.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.bronch.ac.uk/Contents/Item/Display/111</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Respiratory Society Meeting Presentations - September 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>183DE531-5595-42A3-A655-F5156AC5C52C</gtr:id><gtr:impact>Bronch-UK researchers were involved in a number of spoken and poster presentations at the ERS meeting in Amsterdam in September 2015.

Talks:

Heterogeneity in bronchiectasis service provision in Europe: Baseline data from the European bronchiectasis registry (EMBARC). James Chalmers, Eva Polverino, Anthony De Soyza, Felix Ringshausen, Marlene Murris, Wim Boersma, Antoni Torres, Montserrat Vendrell, J. Stuart Elborn, Francesco Blasi, Stefano Aliberti. On Behalf of the EMBARC Clinical Research Collaboration.

Determinants and assessment of excess cardiovascular risk in bronchiectasis. Aarash Saleh, Bessie Kwok, Jeremy Brown, John Hurst

Research priorities in bronchiectasis: A consensus from the European multicentre bronchiectasis audit and research collaboration (EMBARC) study group. Stefano Aliberti, Eva Polverino, Anthony De Soyza, Michael R. Loebinger, Rosario Menendez, Felix C. Ringshausen, Montserrat Vendrell, James D. Chalmers

Posters:

Atorvastatin as an anti-inflammatory in bronchiectasis. Pallavi Bedi, James Chalmers, Adriano Rossi, Adam Hill

Audit investigating self-management of bronchiectasis at University Hospital Llandough, Wales. Sabena Ali, Jamie Duckers, Dawn Lau

The impact of acute air pollution fluctuations on non-cystic fibrosis bronchiectasis pulmonary exacerbations: A case-crossover analysis. Pieter Goeminne, Pallavi Bedi, Michal Kicinski, Lauren Richardson, Kees De Hoogh, Ben Nemery, Tim Nawrot, Michael Loebinger, Adam Hill, Lieven Dupont

Patients in randomized clinical trials of bronchiectasis are only partially representative of clinical practice: A European cohort study. James Chalmers, Melissa McDonnell, Pieter Goeminne, John Davidson, Robert Rutherford, Megan Crichton, Thomas Fardon, Adam Hill, Lieven Dupont, Stefano Aliberti, Anthony De-Soyza

Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB). Anthony De Soyza, Timothy Aksamit, Elisabeth Operschall, Tiemo-Joerg Bandel, Ulrike Krahn, Margarita Criollo, Robert Wilson

Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients. Y.K. Hilliam, A. Perry, A.J. Hall, J. Davison, K.E. Walton, J. Fothergill, A. De Soyza, C. Winstanley</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.bronch.ac.uk/Contents/Item/Display/110</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BronchUK - Microbiology Meeting, British Library, November 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DF5E6366-3474-4080-BC7A-F570EF6F03F3</gtr:id><gtr:impact>A number of leading basic scientists and clinical researchers from within and outwith the BronchUK Network attended this meeting with a focus on microbiology in bronchiectasis. The aims of the meeting were to;
? Identify important microbiology research questions for patients with bronchiectasis
? Define feasible cross-disciplinary experimental approaches to answer these questions, and the most effective and up to date methodologies 
? Begin to plan applications to obtain funding to actually do the required research
? discuss writing review articles in this field to increase profile

The meeting was a success and has led to collaborations and discussions in how to take the key research areas forward.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>iABC (inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis) consortium</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>05B573DF-20C4-499D-ACF1-9ACE83FDBF5B</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Representation on ERS Task Force</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>6AB79F0A-CB54-42BD-92A9-51E102434CA1</gtr:id><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://taskforces.ersnet.org/item/ers-guidelines-on-the-management-of-adult-non-cystic-fibrosis-bronchiectasis</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA9BB78B-7A4D-444F-AC57-748C92CC00B5"><gtr:id>AA9BB78B-7A4D-444F-AC57-748C92CC00B5</gtr:id><gtr:title>Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity.</gtr:title><gtr:parentPublicationTitle>Annals of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6e90bf5d01ad262fba8a51303c57ea66"><gtr:id>6e90bf5d01ad262fba8a51303c57ea66</gtr:id><gtr:otherNames>Lonni S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2325-6621</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11ADE01E-5895-48DB-82A1-9F62DFF42782"><gtr:id>11ADE01E-5895-48DB-82A1-9F62DFF42782</gtr:id><gtr:title>Predictors of adherence to treatment in bronchiectasis.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d632adb7f9c6f91588f6b42524daa37f"><gtr:id>d632adb7f9c6f91588f6b42524daa37f</gtr:id><gtr:otherNames>McCullough AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16A9BE24-5B62-46F5-B46E-DAE695C23883"><gtr:id>16A9BE24-5B62-46F5-B46E-DAE695C23883</gtr:id><gtr:title>Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8bb3648455286c522cf185b713455363"><gtr:id>8bb3648455286c522cf185b713455363</gtr:id><gtr:otherNames>Cullen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/10C97330-F578-4715-BE96-02CECEB87EA9"><gtr:id>10C97330-F578-4715-BE96-02CECEB87EA9</gtr:id><gtr:title>Critical care admission trends and outcomes in individuals with bronchiectasis in the UK.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ddeb4b0d25d1d8a565eddbd6154bbd6"><gtr:id>4ddeb4b0d25d1d8a565eddbd6154bbd6</gtr:id><gtr:otherNames>Navaratnam V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F149A8D-D32B-47BA-9F91-AE12767C214A"><gtr:id>5F149A8D-D32B-47BA-9F91-AE12767C214A</gtr:id><gtr:title>Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f64f39cc55653d211eaffe32e196558a"><gtr:id>f64f39cc55653d211eaffe32e196558a</gtr:id><gtr:otherNames>McDonnell MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E347E8E4-DD02-44CB-B8EC-6E179F6C9349"><gtr:id>E347E8E4-DD02-44CB-B8EC-6E179F6C9349</gtr:id><gtr:title>The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B11C900C-0D10-4649-BB16-094F8936C665"><gtr:id>B11C900C-0D10-4649-BB16-094F8936C665</gtr:id><gtr:title>'All illness is personal to that individual': a qualitative study of patients' perspectives on treatment adherence in bronchiectasis.</gtr:title><gtr:parentPublicationTitle>Health expectations : an international journal of public participation in health care and health policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d632adb7f9c6f91588f6b42524daa37f"><gtr:id>d632adb7f9c6f91588f6b42524daa37f</gtr:id><gtr:otherNames>McCullough AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1369-6513</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A4091F87-6C0A-4E0E-BB62-F10E5065B741"><gtr:id>A4091F87-6C0A-4E0E-BB62-F10E5065B741</gtr:id><gtr:title>Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e951b4bd88680d58a75098fd5448ee8a"><gtr:id>e951b4bd88680d58a75098fd5448ee8a</gtr:id><gtr:otherNames>Brill SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7B3AF6E-977D-4167-BADC-CB9A8F8B9435"><gtr:id>B7B3AF6E-977D-4167-BADC-CB9A8F8B9435</gtr:id><gtr:title>Reclaiming the name 'bronchiectasis'.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A71AB8A-52E3-45BE-B8A0-700CF5FA9E47"><gtr:id>9A71AB8A-52E3-45BE-B8A0-700CF5FA9E47</gtr:id><gtr:title>Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c80c07c7085cd51f5d662aa060a5ede"><gtr:id>7c80c07c7085cd51f5d662aa060a5ede</gtr:id><gtr:otherNames>Haworth CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A3AF43F-0161-402F-8D4B-3AD0137C3AEE"><gtr:id>9A3AF43F-0161-402F-8D4B-3AD0137C3AEE</gtr:id><gtr:title>Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f64f39cc55653d211eaffe32e196558a"><gtr:id>f64f39cc55653d211eaffe32e196558a</gtr:id><gtr:otherNames>McDonnell MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57994F36-A354-461F-BE31-628EE1D059C7"><gtr:id>57994F36-A354-461F-BE31-628EE1D059C7</gtr:id><gtr:title>Interventions for enhancing adherence to treatment in adults with bronchiectasis.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a96634ee093a05c0564732db3b75ee2d"><gtr:id>a96634ee093a05c0564732db3b75ee2d</gtr:id><gtr:otherNames>McCullough A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54A7E0FA-7E70-4366-941D-5DC63C72DDB9"><gtr:id>54A7E0FA-7E70-4366-941D-5DC63C72DDB9</gtr:id><gtr:title>Bronchiectasis Rheumatoid overlap syndrome (BROS) is an independent risk factor for mortality in patients with bronchiectasis: A multicentre cohort study.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b031ee868288481475e2973eca6b4a6"><gtr:id>1b031ee868288481475e2973eca6b4a6</gtr:id><gtr:otherNames>De Soyza A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/48A09093-E8D9-4B95-A40C-205D06C977A1"><gtr:id>48A09093-E8D9-4B95-A40C-205D06C977A1</gtr:id><gtr:title>Bronchiectasis and Aspergillus: How are they linked?</gtr:title><gtr:parentPublicationTitle>Medical mycology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b031ee868288481475e2973eca6b4a6"><gtr:id>1b031ee868288481475e2973eca6b4a6</gtr:id><gtr:otherNames>De Soyza A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1369-3786</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB8D6B05-6D5C-479E-AE93-0B4080076477"><gtr:id>FB8D6B05-6D5C-479E-AE93-0B4080076477</gtr:id><gtr:title>Sedentary behaviour and physical activity in bronchiectasis: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3c6b98dcd79977ccfa1ea358f6940348"><gtr:id>3c6b98dcd79977ccfa1ea358f6940348</gtr:id><gtr:otherNames>Bradley JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4A319A05-AD43-43DB-A6F2-6D1F69F396B1"><gtr:id>4A319A05-AD43-43DB-A6F2-6D1F69F396B1</gtr:id><gtr:title>Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c80c07c7085cd51f5d662aa060a5ede"><gtr:id>7c80c07c7085cd51f5d662aa060a5ede</gtr:id><gtr:otherNames>Haworth CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8582EE9D-09AB-42E7-8227-16F20828C25C"><gtr:id>8582EE9D-09AB-42E7-8227-16F20828C25C</gtr:id><gtr:title>COPD-bronchiectasis overlap syndrome.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/30db543f92bcffc0b658fc5987b469f7"><gtr:id>30db543f92bcffc0b658fc5987b469f7</gtr:id><gtr:otherNames>Hurst JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F1A14D5-5B69-4E09-BFC6-B799B13F6516"><gtr:id>8F1A14D5-5B69-4E09-BFC6-B799B13F6516</gtr:id><gtr:title>Defining the content and delivery of an intervention to Change AdhereNce to treatment in BonchiEctasis (CAN-BE): a qualitative approach incorporating the Theoretical Domains Framework, behavioural change techniques and stakeholder expert panels.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d632adb7f9c6f91588f6b42524daa37f"><gtr:id>d632adb7f9c6f91588f6b42524daa37f</gtr:id><gtr:otherNames>McCullough AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A59139E-7541-4D8F-8F47-E1C2EF615D3C"><gtr:id>1A59139E-7541-4D8F-8F47-E1C2EF615D3C</gtr:id><gtr:title>Applying the Transtheoretical Model to Physical Activity Behavior in Individuals With Non-Cystic Fibrosis Bronchiectasis.</gtr:title><gtr:parentPublicationTitle>Respiratory care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b9fc753ef13cfec2b1ff1838498fbb9c"><gtr:id>b9fc753ef13cfec2b1ff1838498fbb9c</gtr:id><gtr:otherNames>Wilson JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0020-1324</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8197A601-805F-4BBE-B2D0-2573400FBA85"><gtr:id>8197A601-805F-4BBE-B2D0-2573400FBA85</gtr:id><gtr:title>Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f64f39cc55653d211eaffe32e196558a"><gtr:id>f64f39cc55653d211eaffe32e196558a</gtr:id><gtr:otherNames>McDonnell MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/195AED1E-EA30-4F3F-9827-EBEC8363E268"><gtr:id>195AED1E-EA30-4F3F-9827-EBEC8363E268</gtr:id><gtr:title>The bronchiectasis severity index. An international derivation and validation study.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/122DD9F2-9E4B-41F5-AE79-DE669A5B7A5C"><gtr:id>122DD9F2-9E4B-41F5-AE79-DE669A5B7A5C</gtr:id><gtr:title>The EMBARC European Bronchiectasis Registry: protocol for an international observational study.</gtr:title><gtr:parentPublicationTitle>ERJ open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2312-0541</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB62F165-7DEA-4135-A9A0-B53DB3F30AAD"><gtr:id>DB62F165-7DEA-4135-A9A0-B53DB3F30AAD</gtr:id><gtr:title>Clinical phenotypes in adult patients with bronchiectasis.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/387c8ba5ccd023893a7c5861a67bd362"><gtr:id>387c8ba5ccd023893a7c5861a67bd362</gtr:id><gtr:otherNames>Aliberti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9594CDD8-3B0E-4FD4-B916-2E68BDE84731"><gtr:id>9594CDD8-3B0E-4FD4-B916-2E68BDE84731</gtr:id><gtr:title>Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b1723e0498997675037f550ba7ba764"><gtr:id>3b1723e0498997675037f550ba7ba764</gtr:id><gtr:otherNames>Quint JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F83A431-DBF2-4BC0-894A-1D6210D1AA8A"><gtr:id>5F83A431-DBF2-4BC0-894A-1D6210D1AA8A</gtr:id><gtr:title>Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f88230df52c8069cfba3016a3458c93"><gtr:id>5f88230df52c8069cfba3016a3458c93</gtr:id><gtr:otherNames>Wilson R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A5764CC2-3567-40FB-BDB6-94314EE5DAE2"><gtr:id>A5764CC2-3567-40FB-BDB6-94314EE5DAE2</gtr:id><gtr:title>Bronchiectasis: how to be an orphan with many parents?</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81d0b2a56cadd87ab852a383e13aa3f9"><gtr:id>81d0b2a56cadd87ab852a383e13aa3f9</gtr:id><gtr:otherNames>Goeminne PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FF0CA534-44EC-48D5-97E2-701ADDB97623"><gtr:id>FF0CA534-44EC-48D5-97E2-701ADDB97623</gtr:id><gtr:title>Telomere Dysfunction and Senescence-associated Pathways in Bronchiectasis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cfbb91681dda4bf4d3b4500010250fba"><gtr:id>cfbb91681dda4bf4d3b4500010250fba</gtr:id><gtr:otherNames>Birch J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L011263/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>